PHI-55: (NCI#7427): A phase I study of halichondrin B analog (E7389) in combination with cisplatin (CDDP) in advanced solid tumors: A CCC, NCI/CTEP-sponsored trial (grant U01 CA 062505).

Marianna Koczywas,Heinz-Josef Lenz,Joanne E. Mortimer,Anthony B. El-Khoueiry,Paul Frankel,David R. Gandara,Mihaela C. Cristea,Vincent Chung,Dean Lim,Karen L. Reckamp,Derick H Lau,Wei Ye,L. Austin Doyle,Mary Carroll,Edward M. Newman

PHI-55: (NCI#7427): A phase I study of halichondrin B analog (E7389) in combination with cisplatin (CDDP) in advanced solid tumors: A CCC, NCI/CTEP-sponsored trial (grant U01 CA 062505).

2017

Marianna Koczywas
Heinz-Josef Lenz
Joanne E. Mortimer
Anthony B. El-Khoueiry
Paul Frankel
David R. Gandara
Mihaela C. Cristea
Vincent Chung
Dean Lim
Karen L. Reckamp
Derick H Lau
Wei Ye
L. Austin Doyle
Mary Carroll
Edward M. Newman

2564 Background: E7389 is a structurally simplified synthetic macrocyclic ketone analog of the marine sponge natural product Halichondrin B, which inhibits microtubule dynamics via a novel mechanis...

Keywords:

Pathology
Cancer research
Cisplatin
Halichondrin B
Natural product
Microtubule dynamics
Medicine
Halichondrin B Analog
Ketone
phase i study

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations